Built on proprietary technology, EndeavorOTC and EndeavorRx present specific sensory stimuli and simultaneous motor challenges designed to target neural systems in the brain related to attentional control. This technology includes an adaptive “challenge algorithm” that automatically adjusts the difficulty level to each patient’s individual needs, so that they are strengthening attentional control over time. The technology behind these products has been rigorously evaluated across multiple clinical studies in patients diagnosed with ADHD, including STARS-ADHD, a prospective, randomized, controlled study published in The Lancet Digital Health.
REFERENCES
ADHD POC: Naomi O. Davis, Jeffrey Bower, and Scott H. Kollins, “Proof-of-Concept Study of an at-Home, Engaging, Digital Intervention for Pediatric ADHD,” PLoS One 13, no. 1 (2018): e0189749, https://doi.org/10.1371/journal.pone.0189749. STARS-ADHD: Scott H. Kollins et al., “A Novel Digital Intervention for Actively Reducing Severity of Paediatric ADHD (STARS-ADHD): A Randomised Controlled Trial,” The Lancet Digital Health 2, no. 4 (April 1, 2020): e168–78, https://doi.org/10.1016/S2589-7500(20)30017-0. ASD Pilot: Benjamin Yerys et al., “Brief Report: Pilot Study of a Novel Interactive Digital Treatment to Improve Cognitive Control in Children with Autism Spectrum Disorder and Co-Occurring ADHD Symptoms,” Journal of Autism and Developmental Disorders 49, no. 4 (2019): 1727–37, https://doi.org/10.1007/s10803-018-3856-7. And SPD: Anguera, J. A., Brandes-Aitken, A. N., Antovich, A. D., Rolle, C. E., Desai, S. S., & Marco, E. J. (2017). A pilot study to determine the feasibility of enhancing cognitive abilities in children with sensory processing dysfunction. PloS one, 12(4). STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress)
Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported.
EndeavorRx is only available through a licensed health care provider. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child’s medication. EndeavorRx may not be appropriate for patients with photo-sensitive epilepsy, color blindness, or physical limitations that restrict use of a mobile device; parents should consult with their child’s health care provider.
Families should contact their child’s health care provider and review the important indications, safety and caution information in the Instructions for Use before using the EndeavorRx treatment.
For more information, visit EndeavorRx.com